Clinical Trial

Thoraco Lumbar Vertebral Length and Bupivacaine Dosage in C-Section

Study acronym: bupivacaine
Completed
View on ClinicalTrials.gov →
Summary
Our hypothesis is that the bupivacaine dose determined according to the thoracolumbar vertebral body length (VBL) is more effective in achieving a lower hypotension rate during spinal anesthesia for cesarean delivery than the dose usually adjusted based on height and weight. The VBL measurements were determined from the midpoint of C7 to the tuffier line L4 spinous process. Method: Patients ranging in height from 150 to 170 were randomly assigned to either Group 1 (0.2 mg of 0.5% hyperbaric bupivacaine per cm VBL or Group 2 (height-adjusted dose of 0.5% hyperbaric bupivacaine based on a minimum dose of 0.065 mg/cm according to height) or Group 3 (height-adjusted dose of 0.5% hyperbaric bupivacaine based on a minimum height-adjusted dose of 0.065 mg/cm).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-03-10; most recent amendment 2026-04-22.
Status change: Recruiting → Completed 2025-12-17
Status change: Not Yet Recruiting → Recruiting 2025-06-19
Trial Details
NCT Number NCT06869434
Lead Sponsor TC Erciyes University
Conditions Obstetric Anesthesia Problems, Bupivacaine Adverse Reaction
Enrollment 446 participants
Start Date 2025-05-20
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-24